Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2004
Event: Acquisition of KD Scientific, Inc., a Massachusetts corporation specializing in fluidics equipment for research laboratories.
Key Financial Metrics
Transaction Value: Approximately $6.65 million in cash.
Funding Source: Proceeds from a $20 million revolving credit facility with Brown Brothers Harriman & Co.
Escrow Arrangements: Total of $518,405 deposited into escrow, allocated as follows:
- $150,000 for indemnification obligations and post-closing adjustments (release: February 2005).
- $173,090 for potential 2000 tax liabilities (release: April 2004).
- $195,315 for potential 2001 tax liabilities (release: October 2005).
Financial Statements: The filing text does not provide specific revenue, profit, or cash flow metrics for the acquired entity or the combined company at this time. Financial statements and pro forma information are scheduled to be filed by amendment no later than May 17, 2004.
Material Changes
HBIO has expanded its operations through the acquisition of KD Scientific. The company intends to operate KD Scientific as a separate business unit from its existing Holliston, Massachusetts facility. The transaction was negotiated at arm's length with no material relationship between HBIO and the seller, Ken Dunne.
Outlook, Risks, and Contingencies
Forward-Looking Statements: The filing contains forward-looking statements subject to known and unknown risks that may cause actual results to differ materially from anticipated results. The company disclaims any obligation to update these statements.
Contingencies: Portions of the purchase price are held in escrow to cover potential tax liabilities for the years 2000 and 2001, as well as indemnification claims.
Risk Factors: Refer to the "Important Factors That May Affect Future Operating Results" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2003.
Investor Verification Checklist
- Verify the pro forma financial information and financial statements of KD Scientific, Inc. when filed by May 17, 2004.
- Review the Stock Purchase Agreement (Exhibit 2.1) for specific terms regarding indemnification and purchase price adjustments.
- Monitor the release of escrow funds in April 2004, February 2005, and October 2005 to assess if any claims were made against the $518,405 held.
- Assess the impact of the $6.65 million cash outflow on HBIO's remaining capacity under its $20 million revolving credit facility.